Skip to content

US · CARL · MEDICAL - DEVICES

Carlsmed, Inc. (CARL) intrinsic value and stock valuation

$17.42as of 2026-11-21 · Mkt cap 375.7M

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Carlsmed, Inc. DCF and intrinsic value

InvestorsCraft values CARL with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from CARL’s statements →

Carlsmed, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Carlsbad, CA 92008 carlsmed.com

How the business is doing

Fiscal 2023–2025, USD

Revenue
$50.5M
20232025
Net income
-$-29.63M
20232025
Free cash flow
-$-29.62M
20232025
Total equity
$98.9M
20232025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2023–2025, USD
202520242023
Revenue$50.5M$27.2M$13.8M
Operating income-$-30.57M-$-24.12M-$-18.59M
Net income-$-29.63M-$-24.26M-$-18.9M
EPSd-$-2.08M-$-1.46M-$-4.25M
Operating cash flow-$-28.98M-$-25.47M-$-17.48M
Capital expenditure-$-640K-$-180K-$-140K
Free cash flow-$-29.62M-$-25.65M-$-17.61M
Total assets$130.1M$51.8M$14M
Total debt$17.4M$17.2M$11.4M
Net debt-$-68.38M-$-22.95M$4.17M
Total equity$98.9M-$-70.63M-$-46.13M
Cash and short-term investments$109.8M$40.1M$7.22M
Income statement
202520242023
Revenue$50.5M$27.2M$13.8M
Cost of revenue$12.5M$7.12M$3.88M
Gross profit$38M$20.1M$9.9M
Research and development expenses$17M$14.3M$7.39M
Selling, general and administrative expenses$51.6M$29.9M$21.1M
Other expenses$0.00$0.00$0.00
Operating expenses$68.6M$44.2M$28.5M
Cost and expenses$81.1M$51.3M$32.4M
Interest income$2.7M$1.33M$330K
Interest expense$1.43M$1.32M$640K
Depreciation and amortization$280K$140K$140K
Ebitda-$-27.92M-$-22.79M-$-18.12M
Operating income-$-30.57M-$-24.12M-$-18.59M
Total other income/expenses, net$940K-$-140K-$-310K
Income before tax-$-29.63M-$-24.26M-$-18.9M
Income tax expense$0.00$0.00$0.00
Net income-$-29.63M-$-24.26M-$-18.9M
Weighted average shares outstanding$14.2M$16.6M$4.45M
Weighted average diluted shares outstanding$14.2M$16.6M$4.45M
Balance sheet
202520242023
Cash and short-term investments$109.8M$40.1M$7.22M
Net receivables$11.4M$6.77M$3.17M
Inventory$1.84M$990K$570K
Total current assets$126.7M$49.4M$11.8M
Property, plant and equipment, net$3.31M$1.9M$2.24M
Goodwill and intangible assets$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00
Total non-current assets$3.45M$2.47M$2.26M
Total assets$130.1M$51.8M$14M
Accounts payable$4.48M$2.41M$1.69M
Short-term debt$750K$450K$2.15M
Deferred revenue$0.00$0.00$0.00
Total current liabilities$14.3M$8.82M$7.44M
Long-term debt$16.7M$16.7M$9.24M
Deferred revenue, non-current$0.00$0.00$0.00
Total non-current liabilities$17M$113.6M$52.7M
Capital lease obligations$2.07M$1.32M$2.08M
Total liabilities$31.3M$122.5M$60.2M
Common stock$0.00$0.00$0.00
Retained earnings-$-100.81M-$-71.17M-$-46.91M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00
Total equity$98.9M-$-70.63M-$-46.13M
Total investments$24M$0.00$0.00
Total debt$17.4M$17.2M$11.4M
Net debt-$-68.38M-$-22.95M$4.17M
Cash flow statement
202520242023
Net income-$-29.63M-$-24.26M-$-18.9M
Depreciation and amortization$280K$140K$140K
Stock-based compensation$1.93M$250K$120K
Change in working capital-$-4.89M-$-4.08M-$-890K
Accounts receivable-$-5.01M-$-3.97M-$-2.43M
Inventory-$-2.69M-$-1.8M-$-910K
Accounts payable$2.32M$300K$940K
Net cash provided by operating activities-$-28.98M-$-25.47M-$-17.48M
Investments in property, plant and equipment-$-640K-$-180K-$-140K
Acquisitions, net$0.00$0.00$0.00
Net cash used for investing activities-$-25.48M-$-180K-$-140K
Common stock issued$93.7M$0.00$60K
Common stock repurchased$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00
Net cash used for financing activities$100.1M$58.5M$3.18M
Net change in cash$45.7M$32.9M-$-14.44M
Cash at end of period$85.9M$40.2M$7.37M
Operating cash flow-$-28.98M-$-25.47M-$-17.48M
Capital expenditure-$-640K-$-180K-$-140K
Free cash flow-$-29.62M-$-25.65M-$-17.61M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Carlsmed, Inc.

        Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.

        CEO
        Michael Cordonnier
        Employees
        127
        Beta
        1.77

        Explore

        Frequently asked questions

        What is the intrinsic value of Carlsmed, Inc. (CARL)?

        Carlsmed, Inc. (CARL) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is CARL undervalued?

        CARL trades at a price of $17.42 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.